Test Price
2,800 AED✅ Home Collection Available
LMNB1 Gene (Autosomal Dominant Adult-Onset Demyelinating Leukodystrophy) Genetic Test in Dubai | 2800 AED
Executive Summary & Core Metrics
Diagnostic Sensitivity: 99.9% via ISO 9001:2015‑certified next‑generation sequencing (NGS) for LMNB1 duplication detection.
Specimen Matrix: Peripheral whole blood, extracted genomic DNA, or FTA card – standard venipuncture collection.
Turnaround Time: 3–4 weeks from sample receipt to final interpreted report.
Clinical Oversight: Post‑test telephonic interpretation by a DHA‑licensed Consultant Medical Geneticist.
Insurance Billing: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The LMNB1 gene NGS test diagnoses autosomal dominant adult‑onset demyelinating leukodystrophy (ADLD) by detecting pathogenic LMNB1 duplications with base‑pair resolution. This single‑gene analysis employs full‑gene next‑generation sequencing to identify all duplication sizes and breakpoints, thereby eliminating the blind spots inherent in targeted MLPA or PCR‑based assays. The result is a definitive molecular diagnosis that informs prognosis, family counseling, and clinical management.
| Feature | Our LMNB1 NGS Test | Closest Alternative (PCR‑/MLPA‑based) |
|---|---|---|
| Methodology | Full‑gene NGS – detects all duplication sizes and breakpoints | Targeted MLPA/PCR – limited to known hot‑spot duplications |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139), DHA‑licensed facility | Variable – may lack international accreditation |
Physician Insight & Safety Protocols
“A positive LMNB1 duplication provides a definitive molecular diagnosis of adult‑onset demyelinating leukodystrophy, but the test result must always be interpreted alongside clinical presentation, neurological examination, and brain MRI findings. The duplication itself does not predict rate of progression or severity. Patients and families should receive pre‑ and post‑test genetic counseling to understand the autosomal dominant inheritance pattern and implications for at‑risk relatives.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Notice – Medication & Clinical Management
Do not discontinue, adjust, or initiate any prescribed neurological medication based solely on a genetic test result. Always consult your treating neurologist or the referring physician for medication management decisions. The LMNB1 duplication status informs diagnosis, not acute therapeutic guidance.
Exclusion Criteria & Emergency Red Flags
This test is not appropriate for:
- Prenatal diagnosis or carrier testing in asymptomatic minors without a confirmed parental LMNB1 mutation.
- Acute neurological decompensation – sudden confusion, new‑onset seizures, rapid vision loss, or rapidly progressive motor weakness require immediate emergency evaluation, not a scheduled genetic test.
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM for standard venipuncture. All collections performed by licensed phlebotomists under aseptic protocols.
Patient FAQ & Clinical Guidance
1. What does the LMNB1 gene test diagnose?
This test detects duplications in the LMNB1 gene that cause autosomal dominant adult‑onset demyelinating leukodystrophy (ADLD). ADLD is a progressive neurological disorder characterized by white matter degeneration in the central nervous system, typically presenting in the fourth or fifth decade of life with autonomic dysfunction, motor deficits, and cognitive changes. A positive result confirms the molecular diagnosis and enables family screening.
2. How is the sample collected and what preparation is required?
A licensed phlebotomist collects a peripheral whole blood sample via standard venipuncture (two EDTA tubes, 4–6 mL total). Alternatively, a finger‑prick FTA card or extracted genomic DNA can be accepted. No fasting is required. The sample is transported under ISO‑certified temperature‑controlled cold chain to our Dubai Healthcare City laboratory. Home collection is available daily between 8 AM and 11 PM.
3. When will results be available and who interprets them?
Results are delivered within 3 to 4 weeks from sample receipt. The final report includes a comprehensive interpretation by a DHA‑licensed Consultant Medical Geneticist. A post‑test teleconsultation is available to discuss results, inheritance patterns, and family screening recommendations. Reports are delivered electronically via secure patient portal and in hard copy upon request.
4. Can this test predict disease severity or age of onset?
No. The presence of an LMNB1 duplication confirms the diagnosis but does not predict individual disease trajectory, severity, or age of symptom onset. Penetrance is high but variable, and modifying genetic, epigenetic, and environmental factors are not yet fully understood. Clinical correlation with neurological examination and imaging remains essential.
5. Is genetic counseling available for family members?
Yes. Because ADLD follows an autosomal dominant inheritance pattern, each first‑degree relative of an affected individual has a 50% risk of inheriting the duplication. We offer comprehensive pre‑ and post‑test genetic counseling for the patient and at‑risk family members, including cascade testing options. Counseling sessions are conducted by our Consultant Medical Geneticist.
UAE Regulatory & Data Privacy Adherence
All genetic testing services at DNA Labs UAE fully comply with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring your genetic and identifying data are processed lawfully, transparently, and with explicit consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing the secure storage, transmission, and access of electronic health and genetic records within UAE jurisdiction.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – establishing the standard of care for clinical genetic testing, patient consent, and the professional accountability of the ordering and interpreting physicians.
All genetic data is encrypted end‑to‑end, stored on UAE‑based servers, and never shared with third parties without your explicit written authorization. Routine audits and ISO 9001:2015 certification reinforce our commitment to data security and clinical excellence.
Clinical & Logistical Metadata
| Test Name | LMNB1 Gene (Autosomal Dominant Adult-Onset Demyelinating Leukodystrophy) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (2 × EDTA tubes, 4–6 mL total), extracted genomic DNA, or FTA card – standard venipuncture; VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Full‑gene Next‑Generation Sequencing (NGS) – detection of LMNB1 duplications of all sizes and breakpoints |
| ICD-10-CM Code | E75.24 |
| LOINC Code | 21636-7 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians